1. Home
  2. SFST vs GYRE Comparison

SFST vs GYRE Comparison

Compare SFST & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern First Bancshares Inc.

SFST

Southern First Bancshares Inc.

N/A

Current Price

$59.35

Market Cap

565.5M

Sector

Finance

ML Signal

N/A

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

N/A

Current Price

$4.62

Market Cap

625.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SFST
GYRE
Founded
1999
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
565.5M
625.6M
IPO Year
2012
2004

Fundamental Metrics

Financial Performance
Metric
SFST
GYRE
Price
$59.35
$4.62
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
★ $68.75
$18.67
AVG Volume (30 Days)
67.3K
★ 144.2K
Earning Date
10-20-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 94.76
N/A
EPS
★ 3.68
N/A
Revenue
★ $6,282,000.00
$275,000.00
Revenue This Year
$23.97
N/A
Revenue Next Year
$17.69
$27.49
P/E Ratio
$16.70
★ N/A
Revenue Growth
★ 12.99
N/A
52 Week Low
$46.80
$4.27
52 Week High
$65.09
$9.14

Technical Indicators

Market Signals
Indicator
SFST
GYRE
Relative Strength Index (RSI) 44.60 36.84
Support Level $58.70 N/A
Resistance Level $60.83 $7.37
Average True Range (ATR) 1.93 0.55
MACD -0.11 -0.18
Stochastic Oscillator 9.16 21.73

Price Performance

Historical Comparison
SFST
GYRE

About SFST Southern First Bancshares Inc.

Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: